While the role of certain targeted therapy is well established in specific tumor types, such as the use of ALK inhibitors in ALK-rearranged non-small cell adenocarcinoma, the efficacy of tissue-agnostic therapy when used off-label and off-clinical trials may not be well characterized [31]. The gene discussed is ALK; the disease is neoplasm.